301 related articles for article (PubMed ID: 24185941)
1. Evidence for innate immune system activation in HIV type 1-infected elite controllers.
Krishnan S; Wilson EM; Sheikh V; Rupert A; Mendoza D; Yang J; Lempicki R; Migueles SA; Sereti I
J Infect Dis; 2014 Mar; 209(6):931-9. PubMed ID: 24185941
[TBL] [Abstract][Full Text] [Related]
2. Is low-level HIV-1 viraemia associated with elevated levels of markers of immune activation, coagulation and cardiovascular disease?
Elvstam O; Medstrand P; Jansson M; Isberg PE; Gisslén M; Björkman P
HIV Med; 2019 Oct; 20(9):571-580. PubMed ID: 31148335
[TBL] [Abstract][Full Text] [Related]
3. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.
Hunt PW; Brenchley J; Sinclair E; McCune JM; Roland M; Page-Shafer K; Hsue P; Emu B; Krone M; Lampiris H; Douek D; Martin JN; Deeks SG
J Infect Dis; 2008 Jan; 197(1):126-33. PubMed ID: 18171295
[TBL] [Abstract][Full Text] [Related]
4. Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection.
Wilson EM; Singh A; Hullsiek KH; Gibson D; Henry WK; Lichtenstein K; Önen NF; Kojic E; Patel P; Brooks JT; Sereti I; Baker JV;
J Infect Dis; 2014 Nov; 210(9):1396-406. PubMed ID: 24813472
[TBL] [Abstract][Full Text] [Related]
5. Rapid development of HIV elite control in a patient with acute infection.
Morley D; Lambert JS; Hogan LE; De Gascun C; Redmond N; Rutishauser RL; Thanh C; Gibson EA; Hobbs K; Bakkour S; Busch MP; Farrell J; McGetrick P; Henrich TJ
BMC Infect Dis; 2019 Sep; 19(1):815. PubMed ID: 31533639
[TBL] [Abstract][Full Text] [Related]
6. Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers.
Ganesh A; Lemongello D; Lee E; Peterson J; McLaughlin BE; Ferre AL; Gillespie GM; Fuchs D; Deeks SG; Hunt PW; Price RW; Spudich SS; Shacklett BL
AIDS Res Hum Retroviruses; 2016 Aug; 32(8):791-800. PubMed ID: 27019338
[TBL] [Abstract][Full Text] [Related]
7. Monocyte Based Correlates of Immune Activation and Viremia in HIV-Infected Long-Term Non-Progressors.
Prabhu VM; Singh AK; Padwal V; Nagar V; Patil P; Patel V
Front Immunol; 2019; 10():2849. PubMed ID: 31867010
[No Abstract] [Full Text] [Related]
8. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers.
Pereyra F; Lo J; Triant VA; Wei J; Buzon MJ; Fitch KV; Hwang J; Campbell JH; Burdo TH; Williams KC; Abbara S; Grinspoon SK
AIDS; 2012 Nov; 26(18):2409-12. PubMed ID: 23032411
[TBL] [Abstract][Full Text] [Related]
9. Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication
Jacobs ES; Keating SM; Abdel-Mohsen M; Gibb SL; Heitman JW; Inglis HC; Martin JN; Zhang J; Kaidarova Z; Deng X; Wu S; Anastos K; Crystal H; Villacres MC; Young M; Greenblatt RM; Landay AL; Gange SJ; Deeks SG; Golub ET; Pillai SK; Norris PJ
J Virol; 2017 Mar; 91(6):. PubMed ID: 28053103
[TBL] [Abstract][Full Text] [Related]
10. HIV-DNA content in pTfh cells is associated with residual viremia in elite controllers.
García M; Morcilla V; Navarrete-Muñoz MÁ; Fisher K; Cabello A; López-Bernaldo JC; De La Hera F; Barros C; Fernández-Guerrero M; Estrada V; Górgolas M; Benito JM; Palmer S; Rallón N
AIDS; 2021 Mar; 35(3):393-398. PubMed ID: 33252487
[TBL] [Abstract][Full Text] [Related]
11. Expression profile of host restriction factors in HIV-1 elite controllers.
Abdel-Mohsen M; Raposo RA; Deng X; Li M; Liegler T; Sinclair E; Salama MS; Ghanem Hel-D; Hoh R; Wong JK; David M; Nixon DF; Deeks SG; Pillai SK
Retrovirology; 2013 Oct; 10():106. PubMed ID: 24131498
[TBL] [Abstract][Full Text] [Related]
12. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters.
Pereyra F; Palmer S; Miura T; Block BL; Wiegand A; Rothchild AC; Baker B; Rosenberg R; Cutrell E; Seaman MS; Coffin JM; Walker BD
J Infect Dis; 2009 Sep; 200(6):984-90. PubMed ID: 19656066
[TBL] [Abstract][Full Text] [Related]
13. Normal T-cell activation in elite controllers with preserved CD4+ T-cell counts.
Bansal A; Sterrett S; Erdmann N; Westfall AO; Dionne-Odom J; Overton ET; Goepfert PA
AIDS; 2015 Nov; 29(17):2245-54. PubMed ID: 26544698
[TBL] [Abstract][Full Text] [Related]
14. Effect of antiretroviral therapy on HIV reservoirs in elite controllers.
Chun TW; Shawn Justement J; Murray D; Kim CJ; Blazkova J; Hallahan CW; Benko E; Costiniuk CT; Kandel G; Ostrowski M; Kaul R; Moir S; Casazza JP; Koup RA; Kovacs C; Fauci AS
J Infect Dis; 2013 Nov; 208(9):1443-7. PubMed ID: 23847057
[TBL] [Abstract][Full Text] [Related]
15. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses.
Owen RE; Heitman JW; Hirschkorn DF; Lanteri MC; Biswas HH; Martin JN; Krone MR; Deeks SG; Norris PJ;
AIDS; 2010 May; 24(8):1095-105. PubMed ID: 20400885
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers.
Vigneault F; Woods M; Buzon MJ; Li C; Pereyra F; Crosby SD; Rychert J; Church G; Martinez-Picado J; Rosenberg ES; Telenti A; Yu XG; Lichterfeld M
J Virol; 2011 Mar; 85(6):3015-9. PubMed ID: 21177805
[TBL] [Abstract][Full Text] [Related]
17. Antigen Presenting Cells Contribute to Persistent Immune Activation Despite Antiretroviral Therapy Initiation During Hyperacute HIV-1 Infection.
Naidoo KK; Ndumnego OC; Ismail N; Dong KL; Ndung'u T
Front Immunol; 2021; 12():738743. PubMed ID: 34630420
[TBL] [Abstract][Full Text] [Related]
18. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.
Hatano H; Delwart EL; Norris PJ; Lee TH; Dunn-Williams J; Hunt PW; Hoh R; Stramer SL; Linnen JM; McCune JM; Martin JN; Busch MP; Deeks SG
J Virol; 2009 Jan; 83(1):329-35. PubMed ID: 18945778
[TBL] [Abstract][Full Text] [Related]
19. Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy.
McCausland MR; Juchnowski SM; Zidar DA; Kuritzkes DR; Andrade A; Sieg SF; Lederman MM; Funderburg NT
PLoS One; 2015; 10(10):e0139474. PubMed ID: 26430882
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers.
Li JZ; Segal FP; Bosch RJ; Lalama CM; Roberts-Toler C; Delagreverie H; Getz R; Garcia-Broncano P; Kinslow J; Tressler R; Van Dam CN; Keefer M; Carrington M; Lichterfeld M; Kuritzkes D; Yu XG; Landay A; Sax PE;
Clin Infect Dis; 2020 Apr; 70(8):1636-1642. PubMed ID: 31131858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
